Hainan Shuangcheng Pharmaceuticals Co Ltd. Stock Analysis 002693.SZ

Hainan Shuangcheng Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of chemically synthesized peptide drugs. The company is headquartered in Haikou, Hainan and currently employs 448 full-time employees. The company went IPO on 2012-08-08. The firm operates its business through three segments. The Self-Production Pharmaceutical Sales segment produces and sells peptide drugs, as well as other pharmaceuticals such as bivalirudin for injection, famotidine for injection, and clindamycin hydrochloride for injection. The Trust Business segment provides research, development and technical services to other pharmaceutical companies. The Other Business segment primarily acts as an agent for other companies' pharmaceutical sales, as well as leasing land and buildings. The firm mainly conducts its businesses in the domestic market.